症状性心力衰竭和与急性髓性白血病患者的克隆性血液形成相关突变
Yu Kang1, Benedicte Lefebvre1, Ingrid Marti Pamies1
1Division of Cardiovascular Disease, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
不确定潜力 (CHIP) 突变的克隆造血,特别是DNMT3A,在急性髓性白血病 (AML) 患者中增加心力衰竭风险. 这一发现强调了CHIP和AML中心血管并发症之间的显著关联.
科学领域:
- 血液学 血液学 血液学
- 心血管医学 心血管医学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 不确定潜力的克隆性血液形成 (CHIP) 是已知的血液恶性瘤和心血管疾病的风险因素.
- 了解CHIP对特定患者群体的心血管健康的影响至关重要,比如急性髓性白血病 (AML) 患者.
研究的目的:
- 调查CHIP相关突变与新诊断AML的患者症状性心力衰竭 (HF) 的发展之间的关联.
- 为了确定与AML患者中HF风险增加相关的特定CHIP突变.
主要方法:
- 对563名新诊断的AML患者进行回顾性分析,这些患者接受了治疗前的骨髓DNA测序.
- 利用Cox的比例危险和Fine和Gray的分发危险回归模型来评估CHIP突变和症状性HF之间的关系.
- 评估了与特定CHIP突变相关的症状性HF的发生率和累积发生率,包括DNMT3A,ASXL1和TET2.
主要成果:
- 观察到CHIP的高患病率,79.0%的患者患有至少一种与CHIP相关的突变 (DNMT3A,ASXL1,TET2最常见).
- 症状性HF在9.1%的患者中发生;DNMT3A突变患者的发病率显著高 (1年累计发病率为11.4%vs3.9%).
- DNMT3A突变独立地与症状性HF风险增加两倍相关 (HR 2.32,95% CI 1.26-4.29),即使根据年龄和环素剂量进行调整.
结论:
- 在AML患者中,DNMT3A突变的存在与显著增加患有症状性心力衰竭的风险有关.
- 这种关联不论患者的年龄或是对抗环素药物治疗的程度如何,都会持续存在,这表明DNMT3A是AML中心血管风险的潜在生物标志物.
- 需要进一步的研究来阐明DNMT3A突变与AML中的HF之间联系的机制.
更多相关视频
06:28Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
Published on: November 10, 2023
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
相关概念视频
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Regulation of Hematopoietic Stem Cells
Differentiation of Common Myeloid Progenitor Cells
Hematopoiesis
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
